Recruiting
Phase 4

Antibiotic Instillation vs. Oral Therapy

Sponsor:

Atlantic Health System

Code:

NCT04285320

Conditions

Recurrent Urinary Tract Infection

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Intravesical antibiotic instillation

Antibiotic oral suppressive therapy

Study Details

Brief summary:

This is a research study that aims to determine if antibiotic bladder instillations (placing an antibiotic directly into the bladder) over several sessions at the office is a good option to prevent recurrent urinary tract infections, in comparison with oral suppression therapy (taking daily antibiotics in the form of pills by mouth). Oral antibiotic suppression therapy is currently the most common treatment route for recurrent urinary tract infections in post-menopausal women. The bladder antibiotic instillation may overcome the disadvantages of oral suppression therapy such as antibiotic resistance, certain side effects, and recurrence of infections after finishing the treatment course.

Conditions

Recurrent Urinary Tract Infection

Study ID

NCT04285320

Start date

Jun 11, 2021

Status verified date

Nov, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Jun, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Post-menopausal women with recurrent urinary tract infections (2 infections in a 6-month period or at least 3 infections in a 1-year period)
  • Receiving estrogen vaginal therapy for 1 month prior to enrollment
  • Able to come in to the office twice weekly for 3-4 weeks
  • English speaking
  • No allergy to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.
  • No uro-pathogen resistance to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.

Exclusion Criteria:

  • Allergy to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
  • Recent Urine culture with pathogens resistant to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
  • Renal failure (Creatinine clearance <30ml/min)
  • History of urinary retention
  • History of genitourinary structural abnormalities

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

active comparator: Intravesical antibiotic instillation

active comparator: Oral antibiotic suppressive therapy

Interventions

Intravesical antibiotic instillation

Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:

  • Amikacin-30 mg in 60 ml of sterile water
  • Gentamycin-80mg in 60ml sterile water
  • Tobramycin-80 mg in 100 ml of sterile water

Antibiotic oral suppressive therapy

In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:

  • Trimethoprim daily (100 mg)
  • Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)
  • Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)
  • Nitrofurantoin monohydrate/macrocrystals daily (50 mg)
  • Nitrofurantoin monohydrate/macrocrystals daily (100 mg)
  • Cephalexin daily (125 mg)
  • Cephalexin daily (250 mg)
  • Fosfomycin every 10 days (3 grams)

Primary outcome measure

  • The percentage of participants with urinary tract infections following treatment course [ Time Frame: Assessed starting immediately after the treatment is completed for a total of 3 months. ]

Central Contacts and Locations

Central contacts

Locations

Atlantic Urogynecology Associates

Recruiting

Morristown, New Jersey, United States, 07960

Contacts

Dipensinh Solanki, MPH

9739717361

Principal Investigator:

Ricardo Caraballo, MD

More Information

Sponsor

Atlantic Health System

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Antibiotic bladder instillation
  • Intravesical antibiotic instillation
  • Oral suppressive therapy
  • Recurrent UTI

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Atlantic Health System on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.